Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ReNeuron's Cell Therapies Attract Fosun Pharma, A Leading Regenerative Medicines Developer

Executive Summary

The UK cell therapy biotech ReNeuron has attracted the healthcare group, Fosun Pharma, which is building up a leading position in regenerative medicine, to develop and commercialize its products in China.

You may also be interested in...



Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.

China's Draft Cell Therapy Guidelines Draws Concern From Industry

New draft guidelines could potentially create parallel clinical pathways for cell and gene therapies in China, and industry executives are worried about different standards for such emerging treatments in a country with the highest number of ongoing cell therapy trials in the world.

Kite Flies CAR-T Into Asia With Daiichi Sankyo, Fosun Deals

Now that Kite Pharma Inc.’s first chimeric antigen receptor T cell (CAR-T) therapy axicabtagene ciloleucel (KTE-C19) is being submitted for US FDA approval, Chairman, President and CEO Arie Belldegrun said it is the right time to think about ways to make the company’s technology available in additional markets, like Japan and China where Kite entered into partnership agreements with Daiichi Sankyo Co. Ltd. and Shanghai Fosun Pharmaceutical Group Co. Ltd., respectively.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125046

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel